Selecta Biosciences Announces Publication in Nature Nanotechnology Describing Novel Approach for Improving the Efficacy and Safety Profile of Biologic Drugs
August 01, 2016 12:53 ET
|
Selecta Biosciences Inc
Published results from preclinical studies show the potential of Selecta’s proprietary SVP-Rapamycin (SEL-110) immune therapy to improve the efficacy and safety of biologic therapeuticsThe data...